Can anything shut down the Gold rally?
NEW YORK - DarioHealth Corp. (NASDAQ:DRIO), a digital health company with a market capitalization of $39.24 million and impressive revenue growth of 42% over the last twelve months, and OneStep announced Monday a strategic collaboration to integrate smartphone-based fall risk assessment technology into Dario’s digital health platform. According to InvestingPro analysis, DRIO appears undervalued at current levels, making this strategic move particularly noteworthy for investors.
The companies have signed a memorandum of understanding and expect to finalize a master services agreement in the coming weeks, according to a press release statement. InvestingPro data reveals that DRIO has demonstrated strong momentum with a 46% price return over the past six months, suggesting growing market confidence in the company’s strategic initiatives.
The integration will incorporate OneStep’s FDA-listed motion-analysis technology, which uses only a smartphone to deliver clinical-grade gait and mobility insights without requiring wearable devices or sensors. The technology aims to provide proactive fall risk identification for high-risk populations, including those with obesity and Medicare Advantage members with frailty and balance issues.
Falls are one of the leading causes of injury among older adults in the U.S., generating more than $50 billion annually in direct medical costs, with Medicare and Medicaid covering approximately 75% of this expense.
"OneStep’s clinical-grade fall risk assessment, requiring no wearables, sensors or calibration, will provide Dario’s members with mobility insights that are both scientifically rigorous and easy to act on," said Steven Nelson, Dario’s President and Chief Commercial Officer.
The collaboration targets specific high-risk groups, including those with obesity, who according to the National Institutes of Health often exhibit poor balance performance and impaired postural stability.
Rachel Lissak, Senior Director of Strategic Partnerships at OneStep, stated, "By bringing ’movement as a vital sign’ into Dario’s ecosystem, OneStep enables proactive care for high-risk members, helping them stay healthier, more independent, and more confident."
DarioHealth provides digital health solutions for chronic conditions including diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health, while OneStep specializes in smartphone-based mobility analysis technology. With a healthy current ratio of 3.3, DarioHealth maintains strong liquidity to support its growth initiatives. For detailed insights and comprehensive analysis, investors can access the full Pro Research Report available on InvestingPro, which covers this and over 1,400 other US equities.
In other recent news, DarioHealth reported its second-quarter 2025 earnings, showing a significant earnings per share (EPS) beat with an EPS of $0.18, surpassing the forecast of -$0.20. However, the company fell short on revenue expectations, posting $5.37 million compared to the anticipated $7.12 million. This revenue miss led Stifel to lower its price target for DarioHealth to $1.25 from $1.50, although it maintained a Buy rating on the stock. The revenue shortfall was attributed to a known client departure, lost revenue from a strategic partner, and slower-than-expected new contract ramps.
Additionally, DarioHealth has been exploring strategic options after receiving multiple unsolicited expressions of interest. The company has formed a special committee and engaged Perella Weinberg as its financial adviser to evaluate potential opportunities, including a sale, merger, or strategic business combination. In another development, DarioHealth announced amendments to the rights of its preferred stockholders, following approval from its board and a majority of the affected stockholders. These recent developments highlight a period of significant activity for DarioHealth as it navigates various strategic and financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.